Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability.
Although change in bone mineral density was the outcome most commonly measured in early clinical trials of osteoporosis therapies, it is now understood that the most clinically important outcome is reduction in the risk of fractures. Of currently available osteoporosis therapies, the bisphosphonates have been most thoroughly investigated in studies with fracture risk as the primary outcome. The most widely studied bisphosphonates include etidronate, alendronate and risedronate. Alendronate and risedronate have the most compelling evidence for vertebral and non-vertebral fracture reduction. This review provides a comprehensive overview of the anti-fracture efficacy of bisphosphonates at the spine, hip, and non-vertebral sites.
Masud
Tahir
T
Clinical Gerontology Research Unit, Department of Medicine, City Hospital, Nottingham, UK. tm@nchhce.demon.co.uk
Giannini
Sandro
S
D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control*; D005938:Glucocorticoids / Q000009:adverse effects; D006615:Hip / Q000473:pathology; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D013131:Spine / Q000473:pathology
D004164:Diphosphonates; D005938:Glucocorticoids